Logo

PharmaShots Weekly Snapshots (March 28 – April 01, 2022)

Share this

PharmaShots Weekly Snapshots (March 28 – April 01, 2022)

Lilly Presents Updated Results of Retevmo (selpercatinib) in P-I/II (LIBRETTO-001) Trial for Advanced RET Fusion-Positive NSCLC at ELCC 2022

Published: Apr 1, 2022 | Tags: Lilly, Retevmo, selpercatinib, P-I/II, LIBRETTO-001, Trial, Advanced, RET Fusion-Positive, NSCLC, ELCC 2022

Corvia Medical Reports Results of Corvia Atrial Shunt in P-III (REDUCE LAP-HF II) Trial for the Treatment of Heart Failure

Published: Apr 1, 2022 | Tags: Corvia Medical, Corvia Atrial Shunt, P-III, REDUCE LAP-HF II Trial, Heart Failure

InflaRx Reports Results of Vilobelimab in the P-III Part of P-II/III (PANAMO) Study for the Treatment of Severe COVID-19

Published: Apr 1, 2022 | Tags: InflaRx, Vilobelimab, P-III, P-II/III, PANAMO Study, COVID-19

Vertex Reports Results of VX-548 in the Two P-II Proof-of-Concept Studies for the Treatment of Acute Pain

Published: Apr 1, 2022 | Tags: Vertex, VX-548, Two, P-II, Proof-of-Concept Studies, Acute Pain

Horizon Reports the New Analysis of Uplizna (inebilizumab-cdon) in the P-III (N-MOmentum) Trial for Neuromyelitis Optica Spectrum Disorder

Published: Apr 1, 2022 | Tags: Horizon, Uplizna, inebilizumab-cdon, P-III, N-MOmentum Trial, Neuromyelitis Optica Spectrum Disorder

Myeloid Entered into an Exclusive Option & Research Collaboration with Prime Medicine to Develop and Accelerate RetroT Technology for Human Diseases

Published: Apr 1, 2022 | Tags: Myeloid, Prime Medicine, RetroT Technology, Human Diseases

JW Therapeutics Receives the NMPA’s IND Clearance for the Clinical Trial of Carteyva (relmacabtagene autoleucel) as 2L Treatment of Large B-Cell Lymphoma

Published: Mar 31, 2022 | Tags: JW Therapeutics, NMPA, IND, Clearance, Carteyva, Large B-Cell Lymphoma

Numab Entered into a Development and License Agreement with Ono to Develop Immuno-Oncology Therapies for the Treatment of Cancer

Published: Mar 31, 2022 | Tags: Numab, Ono, Immuno-Oncology Therapies, Cancer

Immutep & MSD Published New Interim Data of Eftilagimod Alpha + Keytruda (pembrolizumab) in P-II (TACTI-002) Trial as 2L Treatment of NSCLC at ELCC 2022

Published: Mar 31, 2022 | Tags: Immutep, Eftilagimod Alpha, Keytruda, pembrolizumab, P-II, TACTI-002 Trial NSCLC, ELCC 2022

Taiho Oncology Reports the US FDA’s Acceptance of NDA for Priority Review of Futibatinib for the Treatment of Cholangiocarcinoma

Published: Mar 31, 2022 | Tags: Taiho Oncology, US, FDA, NDA, Priority Review, Futibatinib, Cholangiocarcinoma

Iktos Collaboration with Ono to Develop Innovative Therapies Against Diseases and Pain Using AI Technology

Published: Mar 31, 2022 | Tags: Iktos, Ono, Innovative Therapies, Diseases, AI Technology

Organon Enters into a License Agreement with Daré Bioscience to Commercialize Xaciato (clindamycin phosphate vaginal gel) for the Treatment of Bacterial Vaginosis

Published: Mar 31, 2022 | Tags: Organon, Daré Bioscience, Xaciato, clindamycin phosphate vaginal gel, Bacterial Vaginosis

Antengene’s Eltanexor (ATG-016) Receive the NMPA’s IND Approval for P-II Study to Treat Patients with High-Risk Myelodysplastic Syndromes

Published: Mar 30, 2022 | Tags: Antengene, Eltanexor, ATG-016, NMPA, IND, Approval, P-II Study, Myelodysplastic Syndromes

Ocuphire Reports Results of Nyxol in P-III (MIRA-3) Registration Trial for the Reversal of Pharmacologically-Induced Mydriasis

Published: Mar 30, 2022 | Tags: Ocuphire, Nyxol, P-III, MIRA-3, Registration Trial, Pharmacologically-Induced, Mydriasis

ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) Receives the US FDA’s Approval for Virologically Suppressed Adolescents with HIV

Published: Mar 30, 2022 | Tags: ViiV Healthcare, Cabenuva, cabotegravir, rilpivirine, US, FDA, Approval, Virologically Suppressed, Adolescents, HIV

Pfizer Report Results of Etrasimod in P-III (ELEVATE UC 52) Study for the Treatment of Ulcerative Colitis

Published: Mar 30, 2022 | Tags: Everest, Pfizer, Etrasimod, P-III, ELEVATE UC 52, Study Ulcerative Colitis

Pyxis Oncology In-Licenses BSI-060T From Biosion for the Treatment of Solid Tumors

Published: Mar 30, 2022 | Tags: Pyxis Oncology, In-Licenses, BSI-060T, Biosion, Solid Tumors

Albireo Report Enrollment Completion in P-III (ASSERT) Study of Bylvay (odevixibat) for the Treatment of Alagille Syndrome

Published: Mar 30, 2022 | Tags: Albireo, P-III, ASSERT Study, Bylvay, odevixibat, Alagille Syndrome

UCB’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

Published: Mar 29, 2022 | Tags: UCB, Fintepla, fenfluramine, US, FDA, Approval, Seizures, Lennox-Gastaut Syndrome

Takeda’s Takhzyro (lanadelumab) Receives the MHLW’s Approval for the Treatment of Prophylaxis Against Acute Attacks of Hereditary Angioedema

Published: Mar 29, 2022 | Tags: Takeda, Takhzyro, lanadelumab, MHLW, Approval, Prophylaxis, Acute Attacks, Hereditary Angioedema

Boehringer Ingelheim Presents Results of Spesolimab in P-II (Effisayil 1) Trial for the Treatment of Generalized Pustular Psoriasis at AAD 2022

Published: Mar 29, 2022 | Tags: Boehringer Ingelheim, Spesolimab, P-II, Effisayil 1 Trial, Generalized Pustular Psoriasis, AAD 2022

Novo Nordisk’s Ozempic Receives the US FDA’s Approval for the Treatment of Type 2 Diabetes

Published: Mar 29, 2022 | Tags: Novo Nordisk, Ozempic, US, FDA, Approval, Type 2 Diabetes

Sanofi Collaborated with IGM Biosciences to Develop & Commercialize IgM Antibody Agonists Against Oncology, Immunology and Inflammation Targets

Published: Mar 29, 2022 | Tags: Sanofi, IGM Biosciences, IgM Antibody Agonists, Oncology, Immunology, Inflammation Targets

BMS Report EMA's Validation for Opdivo (nivolumab) as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

Published: Mar 29, 2022 | Tags: BMS, EMA, Validation, Opdivo, nivolumab, Resectable, Non-Small Cell Lung Cancer

Ipsen’s Cabometyx Receives CHMP's Recommendation for Approval in the EU to Treat Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Published: Mar 28, 2022 | Tags: Ipsen, EMA, CHMP, Cabometyx, Iodine-Refractory, Differentiated Thyroid Cancer

Merck Receives EMA’s CHMP Positive Opinion for Keytruda (pembrolizumab) to Treat MSI-H or dMMR Tumors in Different Types of Cancer

Published: Mar 28, 2022 | Tags: Merck, EMA, CHMP, Keytruda, pembrolizumab,  MSI-H, dMMR Tumors

Dermavant Presents Results of Tapinarof Cream in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022

Published: Mar 28, 2022 | Tags: Dermavant, Tapinarof Cream, P-III, PSOARING 3 Trial, Plaque Psoriasis, AAD 2022

Arcutis Presents New Pooled Results of Roflumilast in P-III (DERMIS 1 & 2) Trials for the Treatment of Plaque Psoriasis at AAD 2022

Published: Mar 28, 2022 | Tags: Arcutis, Roflumilast, P-III, DERMIS 1 & 2 Trials, Plaque Psoriasis, AAD 2022

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

Published: Mar 28, 2022 | Tags: Gilead, Eisai, EA Pharma, Jyseleca, filgotinib, MHLW, Approval, Ulcerative Colitis

Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness

Published: Mar 28, 2022 | Tags: Axsome, Acquire, Sunosi, Jazz, Excessive Daytime Sleepiness

Related Post: PharmaShots Weekly Snapshots (March 21 - 25, 2022)


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions